ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial
Status:
Completed
Trial end date:
2021-02-10
Target enrollment:
Participant gender:
Summary
The main goal of this study is to evaluate the ability of a single administration of
tocilizumab to reduce myocardial damage in patients presenting with an acute ST-segment
elevation myocardial infarction (STEMI). Secondary objectives are to assess the impact of
treatment on: (i) final infarct size, (ii) left ventricular size and function, (iii)
inflammation, (iv) extracellular matrix remodeling, (v) lipid parameters, (vi) platelet
activation and additional pro- and anti-thrombotic parameters, and (vii) study drug safety
and tolerability.
Phase:
Phase 2
Details
Lead Sponsor:
Oslo University Hospital
Collaborators:
Norwegian University of Science and Technology South-Eastern Norway Regional Health Authority St. Olavs Hospital University of Oslo